FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2171807838> ?p ?o ?g. }

• W2171807838 endingPage "AB44" @default.
• W2171807838 startingPage "AB44" @default.
• W2171807838 abstract "RationaleSwallowed topical corticosteroid treatment is an effective first-line pharmacologic therapy in eosinophilic esophagitis (EoE). However, the impression of a potential adverse effect, growth retardation, has prevented some parents from giving corticosteroids to their children. Clinically, such treatment can alleviate EoE’s symptoms such as food aversion and failure to thrive. Therefore, we hypothesize that treating EoE patients with corticosteroids may lead to the improvement in growth.MethodsThe study includes a retrospective cohort of EoE patients in Children’s Healthcare of Atlanta that were treated with corticosteroid, less than 18 years old, and followed up for at least 6 months. We extracted data, including patients’ demographic information, presenting symptoms, and corticosteroid options, from the health care software Epic. Using before and after treatment standard deviation scores (SDS) for height, we evaluated the significance of our hypothesis by right-tailed Wilcoxon signed-rank test.ResultsSeventeen of 66 patients met the eligibility criteria. Of the 17 patients, the mean age was 6.9 years old and the mean follow up duration was 15.0 months. The p-value was 0.0448, which indicated a significant improvement of patients’ growth after the corticosteroid treatment.ConclusionsNo data have been published to address the impact of corticosteroids on the growth of children with EoE. Through our retrospective study, we showed that corticosteroid treatment contributes to an improvement in the growth in children with EoE, possibly by alleviating EoE symptoms such as food aversions and failure to thrive. RationaleSwallowed topical corticosteroid treatment is an effective first-line pharmacologic therapy in eosinophilic esophagitis (EoE). However, the impression of a potential adverse effect, growth retardation, has prevented some parents from giving corticosteroids to their children. Clinically, such treatment can alleviate EoE’s symptoms such as food aversion and failure to thrive. Therefore, we hypothesize that treating EoE patients with corticosteroids may lead to the improvement in growth. Swallowed topical corticosteroid treatment is an effective first-line pharmacologic therapy in eosinophilic esophagitis (EoE). However, the impression of a potential adverse effect, growth retardation, has prevented some parents from giving corticosteroids to their children. Clinically, such treatment can alleviate EoE’s symptoms such as food aversion and failure to thrive. Therefore, we hypothesize that treating EoE patients with corticosteroids may lead to the improvement in growth. MethodsThe study includes a retrospective cohort of EoE patients in Children’s Healthcare of Atlanta that were treated with corticosteroid, less than 18 years old, and followed up for at least 6 months. We extracted data, including patients’ demographic information, presenting symptoms, and corticosteroid options, from the health care software Epic. Using before and after treatment standard deviation scores (SDS) for height, we evaluated the significance of our hypothesis by right-tailed Wilcoxon signed-rank test. The study includes a retrospective cohort of EoE patients in Children’s Healthcare of Atlanta that were treated with corticosteroid, less than 18 years old, and followed up for at least 6 months. We extracted data, including patients’ demographic information, presenting symptoms, and corticosteroid options, from the health care software Epic. Using before and after treatment standard deviation scores (SDS) for height, we evaluated the significance of our hypothesis by right-tailed Wilcoxon signed-rank test. ResultsSeventeen of 66 patients met the eligibility criteria. Of the 17 patients, the mean age was 6.9 years old and the mean follow up duration was 15.0 months. The p-value was 0.0448, which indicated a significant improvement of patients’ growth after the corticosteroid treatment. Seventeen of 66 patients met the eligibility criteria. Of the 17 patients, the mean age was 6.9 years old and the mean follow up duration was 15.0 months. The p-value was 0.0448, which indicated a significant improvement of patients’ growth after the corticosteroid treatment. ConclusionsNo data have been published to address the impact of corticosteroids on the growth of children with EoE. Through our retrospective study, we showed that corticosteroid treatment contributes to an improvement in the growth in children with EoE, possibly by alleviating EoE symptoms such as food aversions and failure to thrive. No data have been published to address the impact of corticosteroids on the growth of children with EoE. Through our retrospective study, we showed that corticosteroid treatment contributes to an improvement in the growth in children with EoE, possibly by alleviating EoE symptoms such as food aversions and failure to thrive." @default.
• W2171807838 created "2016-06-24" @default.
• W2171807838 creator A5089947111 @default.
• W2171807838 date "2015-02-01" @default.
• W2171807838 modified "2023-09-27" @default.
• W2171807838 title "Impact of Swallowed Topical Steroid Treatment on Growth in Children with Eosinophilic Esophagitis" @default.
• W2171807838 doi "https://doi.org/10.1016/j.jaci.2014.12.1071" @default.
• W2171807838 hasPublicationYear "2015" @default.
• W2171807838 type Work @default.
• W2171807838 sameAs 2171807838 @default.
• W2171807838 citedByCount "0" @default.
• W2171807838 crossrefType "journal-article" @default.
• W2171807838 hasAuthorship W2171807838A5089947111 @default.
• W2171807838 hasBestOaLocation W21718078381 @default.
• W2171807838 hasConcept C126322002 @default.
• W2171807838 hasConcept C167135981 @default.
• W2171807838 hasConcept C187212893 @default.
• W2171807838 hasConcept C197934379 @default.
• W2171807838 hasConcept C2776804153 @default.
• W2171807838 hasConcept C2776917539 @default.
• W2171807838 hasConcept C2779134260 @default.
• W2171807838 hasConcept C2781065132 @default.
• W2171807838 hasConcept C71924100 @default.
• W2171807838 hasConcept C72563966 @default.
• W2171807838 hasConceptScore W2171807838C126322002 @default.
• W2171807838 hasConceptScore W2171807838C167135981 @default.
• W2171807838 hasConceptScore W2171807838C187212893 @default.
• W2171807838 hasConceptScore W2171807838C197934379 @default.
• W2171807838 hasConceptScore W2171807838C2776804153 @default.
• W2171807838 hasConceptScore W2171807838C2776917539 @default.
• W2171807838 hasConceptScore W2171807838C2779134260 @default.
• W2171807838 hasConceptScore W2171807838C2781065132 @default.
• W2171807838 hasConceptScore W2171807838C71924100 @default.
• W2171807838 hasConceptScore W2171807838C72563966 @default.
• W2171807838 hasIssue "2" @default.
• W2171807838 hasLocation W21718078381 @default.
• W2171807838 hasOpenAccess W2171807838 @default.
• W2171807838 hasPrimaryLocation W21718078381 @default.
• W2171807838 hasRelatedWork W1569608259 @default.
• W2171807838 hasRelatedWork W1993512576 @default.
• W2171807838 hasRelatedWork W1995494242 @default.
• W2171807838 hasRelatedWork W2044322370 @default.
• W2171807838 hasRelatedWork W2206686181 @default.
• W2171807838 hasRelatedWork W2472429858 @default.
• W2171807838 hasRelatedWork W2538734629 @default.
• W2171807838 hasRelatedWork W2911515314 @default.
• W2171807838 hasRelatedWork W3113146271 @default.
• W2171807838 hasRelatedWork W3129166186 @default.
• W2171807838 hasVolume "135" @default.
• W2171807838 isParatext "false" @default.
• W2171807838 isRetracted "false" @default.
• W2171807838 magId "2171807838" @default.
• W2171807838 workType "article" @default.